<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The evaluation of the defibrillation threshold (DFT) during the implantation of a cardioverter-defibrillator (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>) is an important stage of the procedure, as a high DFT can be found in up to 16% of patients </plain></SENT>
<SENT sid="1" pm="."><plain>We report a patient with idiopathic <z:hpo ids='HP_0001644'>dilated cardiomyopathy</z:hpo> (<z:chebi fb="20" ids="15767">DCM</z:chebi>) submitted to a biventricular <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> implantation </plain></SENT>
<SENT sid="2" pm="."><plain>During the procedure, the patient showed a high DFT and showed to be resistant to usual therapeutic modalities </plain></SENT>
<SENT sid="3" pm="."><plain>We opted for the azygos vein defibrillation lead implantation, with good resolution </plain></SENT>
</text></document>